Nova EYE Medical Ltd - Asset Resilience Ratio

Latest as of December 2025: 11.08%

Nova EYE Medical Ltd (EYE) has an Asset Resilience Ratio of 11.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Nova EYE Medical Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

AU$2.62 Million
≈ $1.86 Million USD Cash + Short-term Investments

Total Assets

AU$23.67 Million
≈ $16.75 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2001–2025)

This chart shows how Nova EYE Medical Ltd's Asset Resilience Ratio has changed over time. See EYE net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Nova EYE Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Nova EYE Medical Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$2.62 Million 11.08%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$2.62 Million 11.08%

Asset Resilience Insights

  • Moderate Liquidity: Nova EYE Medical Ltd has 11.08% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Nova EYE Medical Ltd Industry Peers by Asset Resilience Ratio

Compare Nova EYE Medical Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Vitrolife AB
ST:VITR
Medical Devices 7.27%
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
Medical Devices 19.31%
Tellgen Corp
SHE:300642
Medical Devices 8.60%
Lumos Diagnostics Holdings Ltd
AU:LDX
Medical Devices 9.40%
T&R Biofab Co. Ltd
KQ:246710
Medical Devices 0.12%
Ok Biotech Co Ltd
TW:4155
Medical Devices 0.32%
Promimic AB
ST:PRO
Medical Devices 8.62%
Memphasys Ltd
AU:MEM
Medical Devices 0.00%

Annual Asset Resilience Ratio for Nova EYE Medical Ltd (2001–2025)

The table below shows the annual Asset Resilience Ratio data for Nova EYE Medical Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 19.07% AU$5.05 Million
≈ $3.58 Million
AU$26.50 Million
≈ $18.75 Million
-1.51pp
2024-06-30 20.58% AU$6.15 Million
≈ $4.35 Million
AU$29.88 Million
≈ $21.14 Million
-3.85pp
2023-06-30 24.44% AU$7.42 Million
≈ $5.25 Million
AU$30.36 Million
≈ $21.48 Million
+2.60pp
2022-06-30 21.84% AU$8.00 Million
≈ $5.66 Million
AU$36.62 Million
≈ $25.91 Million
-20.55pp
2021-06-30 42.39% AU$17.80 Million
≈ $12.60 Million
AU$41.99 Million
≈ $29.71 Million
-39.54pp
2020-06-30 81.93% AU$95.65 Million
≈ $67.68 Million
AU$116.74 Million
≈ $82.60 Million
+66.54pp
2019-06-30 15.39% AU$15.37 Million
≈ $10.88 Million
AU$99.89 Million
≈ $70.68 Million
-6.91pp
2018-06-30 22.29% AU$23.07 Million
≈ $16.32 Million
AU$103.47 Million
≈ $73.21 Million
+11.61pp
2017-06-30 10.68% AU$9.24 Million
≈ $6.54 Million
AU$86.54 Million
≈ $61.23 Million
+10.30pp
2008-06-30 0.38% AU$275.00K
≈ $194.58K
AU$71.94 Million
≈ $50.90 Million
+0.12pp
2007-06-30 0.26% AU$167.00K
≈ $118.16K
AU$63.69 Million
≈ $45.06 Million
+0.16pp
2006-06-30 0.10% AU$46.00K
≈ $32.55K
AU$46.48 Million
≈ $32.88 Million
-42.45pp
2001-06-30 42.54% AU$487.42K
≈ $344.88K
AU$1.15 Million
≈ $810.63K
--
pp = percentage points

About Nova EYE Medical Ltd

AU:EYE Australia Medical Devices
Market Cap
$26.20 Million
AU$37.03 Million AUD
Market Cap Rank
#24155 Global
#985 in Australia
Share Price
AU$0.13
Change (1 day)
+4.00%
52-Week Range
AU$0.10 - AU$0.20
All Time High
AU$0.46
About

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degen… Read more